RE:RE:RE:RE:RE:RE:Quick Summary To put it in a nutshell, I was very annoyed to hear them talking about TH1902 at 300 mg/m2 in humans allowing 10 times more docetaxel in cancer cells than the recommended 80 mg/m2 of docetaxel alone, as if it was a reality. If it's a reality you should have clear efficacy data on humans and not say we will have to wait until phase Ib to see that. Add to that the fact that some patients got at least two cycles at 420 mg/m2. So according to their extrapolations, that would mean those patients got 15 to 20 times the concentration of docetaxel. They should stop talking about the animal data in relation with human patients until they have clear efficacy signal and proof of concept, by that I mean clear tumor shrinkage. That's it.